FDA Approves Pancreatic Enzyme Products to Aid Digestion

02 Mar 2012 --- Ultresa is a delayed-release capsule used to treat children and adults with cystic fibrosis, a serious genetic disorder affecting the lungs and other organs, or other conditions who cannot digest food normally because their pancreas does not make enough pancreatic enzymes.

Mar 2 2012 --- Two new pancreatic enzyme products used to help aid food digestion, Ultresa (pancrelipase) and Viokace (pancrelipase), were approved by the U.S. Food and Drug Administration.

Ultresa is a delayed-release capsule used to treat children and adults with cystic fibrosis, a serious genetic disorder affecting the lungs and other organs, or other conditions who cannot digest food normally because their pancreas does not make enough pancreatic enzymes.

Viokace, in combination with a proton pump inhibitor, is used to treat adults who cannot digest food normally. Adults with chronic pancreatitis, a continuing, chronic inflammatory process of the pancreas, or those who have had some or all of their pancreases removed (pancreatectomy) may not digest food normally because they lack needed enzymes or because their enzymes are not released into the bowel (intestine). Viokace’s safety and efficacy in children has not been established.

“The approvals of Ultresa and Viokace, along with the other approved pancreatic enzyme products, allow health care providers to prescribe the product that is most appropriate for the estimated 200,000 patients in the United States who have pancreatic insufficiency,” said Julie Beitz, M.D., director of the Office of Drug Evaluation III in FDA’s Center for Drug Evaluation and Research.

Ultresa and Viokace are the fourth and fifth pancreatic enzyme products approved by FDA. Other FDA-approved pancreatic enzyme products include Creon (2009), Zenpep (2009) and Pancreaze (2010). Approved pancreatic enzyme products meet FDA standards for safety, efficacy and product quality.

Unapproved pancreatic enzyme products had been available for many years. FDA established a date of April 28, 2010 for the makers of pancreatic enzyme products to stop manufacturing and distributing unapproved products.

Ultresa and Viokace are marketed by Bridgewater, N.J.-based Aptalis Pharma U.S. Inc.
 

Related Articles

Nutrition & Health News

Food for Thought: UK Teenagers Losing Learning Time Due to Hunger

27 Jun 2017 --- Teenage pupils in high school can lose around 51 minutes’ worth of vital learning time a day because their concentration levels dip due to hunger. This is according to the results of a survey conducted in the UK by Kellogg’s. The survey results show that 82 percent of teachers in Britain have seen teens arriving at school hungry every day. And nearly four in 10 teachers believed one reason children in their class were hungry was due to their parents being unable to afford food for breakfast.

Business News

Key Interview: Algatech Targets Synergistic Effects to Advance Microalgae Industry

27 Jun 2017 --- Interest in microalgae has surged over the past decade, and as a result, a growing number of companies have sought to develop new products and technologies to harness the myriad health benefits these unicellular species provide. And according to Algatechnologies, we have only seen the tip of the iceberg in terms of microalgae’s potential benefits and applications. 

Nutrition & Health News

Heightened Risk in Rice? Toxicity of Thioarsenates for Plants Uncovered

27 Jun 2017 --- Although it is a staple food in many regions of the world, rice sometimes contains levels of arsenic that are hazardous to our health. An interdisciplinary team of researchers at the University of Bayreuth has now discovered that there are arsenic compounds which have a toxic effect on plants and yet had not previously been considered in connection with chemical analyses of rice and the estimated health risks for humans. The research concerns thioarsenates, compounds made up of arsenic and sulphur, which may be present in rice fields more often than previously assumed. 

Nutrition & Health News

Nanoparticles as Food Additives due for Risk Reassessment: Researchers

27 Jun 2017 --- The anticaking agent E551 silicon dioxide, or silica, has been used widely in the food industry over the past 50 years, and was long thought to be quite safe. Now, however, researchers working on the National Research Programme “Opportunities and Risks of Nanomaterials” have discovered that these nanoparticles can affect the immune system of the digestive tract.

Business News

Buhler Awarded Contract to Support Food Fortification Program in Pakistan

26 Jun 2017 --- To support the fortification of staple foods in Pakistan, the UK-based Food Fortification Program has awarded Bühler a multi-million contract to supply more than 1000 micro feeders in 2017 and 2018. The program is funded with US$48 million from the UK’s Department for International Development. By directly supporting local mills and food factories, the program is aiming to have a substantial impact on the well-being of close to 100 million people.

More Articles
URL : http://www.nutritioninsight.com:80/news/FDA-Approves-Pancreatic-Enzyme-Products-to-Aid-Digestion.html